Skip to content

Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes

Modulation of Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes of Patients With Parkinson's Disease or Amyotrophic Lateral Sclerosis

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02880033
Acronym
LymphoEnergy
Enrollment
90
Registered
2016-08-26
Start date
2011-02-01
Completion date
2020-03-01
Last updated
2026-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic Lateral Sclerosis, Iron Overload, Oxidative Stress, Parkinson's Disease

Keywords

Parkinson's disease, Amyotrophic lateral sclerosis, Peripheral blood mononuclear cells, ex vivo model for oxidative stress, iron metabolism and chelation

Brief summary

Peripheral blood mononuclear cells (PBMC) and platelets could be interesting ex vivo models to study brain diseases. Indeed, there is no access to neurons from patients. However, PBMC can exhibit different physiopathological mechanisms that are ubiquitous (i.e. oxidative stress, mitochondriopathy with energy metabolism, inflammation, protein folding, iron metabolism and programmed cell death ...). The platelets are pivotal in the healing system with large range of growth factors. A new therapeutic concept of conservative iron chelation with deferiprone for neuroprotection is under development. The action of deferiprone on the different mechanisms and notably the oxidative stress are to obtain from a collection of PBMC and platelets from patient having Parkinson's disease and Amyotrophic lateral sclerosis and healthy controls to study ex vivo. PBMC and platelets will be stored for future analyses.

Detailed description

The study collection of PBMC and platelets from 30 patient having Parkinson's disease 30 patients having Amyotrophic lateral sclerosis and 30 healthy controls. The collection will be performed either by cytapheresis for half of the patient and by collecting the whole blood for the other half. PBMC and platelets will be stored at minus 80°C. PBMC of patients and controls are exposed ex vivo to different pathological condition (mainly Hydrogen peroxide, menadione, hypoxia...) with and without deferiprone to analyse whether the level of oxidative stress (Reactive Oxygen Species and notably hydroxyl radical with hydroxypethidine probe with flow cytometry) is reduced under deferiprone (primary criterion. Secondary analyses will concern the level of iron, the energy metabolism (aerobic versus anaerobic and the level of Adenosine triphosphate production), the type of cell death (apoptosis, autophagy and new programmed cell death: Ferroptosis) and inflammation. Finally, the level of growth factors and their effectiveness will be studied from platelets.

Interventions

DRUGdeferiprone

to test the action of deferiprone on lymphocytes from patients and controls ex vivo

DRUGplacebo

to control the action of placebo on lymphocytes from patients and controls ex vivo

Sponsors

University Hospital, Lille
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Parkinson's disease according to Movement Disorders Society criteria * Amyotrophic Lateral Sclerosis according to El escorial criteria * Age and sex matched healthy controls

Exclusion criteria

* Severe comorbidities (cancer, other degenerative diseases, hemopathy, inflammatory diseases)

Design outcomes

Primary

MeasureTime frameDescription
hydroxyl radical measured12 monthshydroxypethidine probe with Fluorescence-activated cell sorting

Secondary

MeasureTime frameDescription
adenosine triphosphate production measured by seahorse12 monthsseahorse experimentation
oxygen consumption measured by seahorse12 monthsseahorse experimentation
free reactive iron (ferrous iron)12 monthscalceine assay
lipid peroxidation measured by Fluorescence-activated cell sorting12 monthsflow cytometry with bodipy probe

Countries

France

Contacts

PRINCIPAL_INVESTIGATORDavid DEVOS, MD, PhD

University Hospital, Lille

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 15, 2026